Market Cap | 118.92M | P/E | - | EPS this Y | 30.40% | Ern Qtrly Grth | - |
Income | -69.05M | Forward P/E | -9.40 | EPS next Y | 2.30% | 50D Avg Chg | 118.00% |
Sales | 4.53M | PEG | - | EPS past 5Y | - | 200D Avg Chg | 64.00% |
Dividend | N/A | Price/Book | 5.30 | EPS next 5Y | - | 52W High Chg | -33.00% |
Recommedations | 1.50 | Quick Ratio | 1.03 | Shares Outstanding | 36.15M | 52W Low Chg | 296.00% |
Insider Own | 70.35% | ROA | -26.32% | Shares Float | 10.72M | Beta | 0.70 |
Inst Own | 3.63% | ROE | -3,439.35% | Shares Shorted/Prior | 9.89K/13.32K | Price | 3.29 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 146,324 | Target Price | - |
Oper. Margin | -626.90% | Earnings Date | May 9 | Volume | 493,428 | Change | 28.52% |
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Los Angeles, California.
HC Wainwright & Co. | Buy | Mar 22, 24 |
HC Wainwright & Co. | Buy | Aug 14, 23 |
HC Wainwright & Co. | Buy | May 12, 23 |
HC Wainwright & Co. | Buy | Mar 17, 23 |
HC Wainwright & Co. | Buy | Mar 7, 23 |
HC Wainwright & Co. | Buy | Mar 22, 21 |
HC Wainwright & Co. | Buy | May 15, 20 |
HC Wainwright & Co. | Buy | Mar 20, 20 |
Maxim Group | Buy | Feb 6, 20 |